Plasmodium ovale is a cause of non-falciparum malaria infection. Non-falciparum malaria is due to infection caused by Plasmodium species other than P. falciparum. Other causes of non-falciparum malaria infection include P. vivax, P. malariae, and P. knowlesi. Malaria is a protozoan disease transmitted by the bite of infected Anopheles mosquitoes.  It is the most important of the human parasitic diseases. It is transmitted in 107 countries containing more that 3 billion people and causing 1 to 3 million deaths each year. P. ovale malaria is endemic to tropical western Africa. It rarely causes severe illness or death. 
P. ovale malaria like other types of malaria infection begins when a female Anopheles mosquito bites and inoculates plasmodial sporozoites from its salivary gland during feeding. P. ovale may be composed of two coexisting species: Plasmodium ovale curtisi and Plasmodium ovale wallikeri. 
Malaria is present throughout most of the tropical areas of the world. P. ovale malaria is endemic to tropical Western Africa. It is relatively unusual outside of Africa and comprises less than 1% of isolates where found. It is also seen in the Philippines, Indonesia, and Papua New Guinea, but is relatively rare in these areas.  One survey in Indonesia including more than 15,000 blood smears noted 34 individuals with P. ovale infection; the frequency of P. ovale relative to P. falciparum and P. vivax was a ratio less than 1:1000.  Reports of severe P. ovale malaria are rare, possibly due to the relative rarity of P. ovale infection.
The life cycle of P. ovale includes hypnozoites, which are dormant stages in the liver. These stages can be reactivated in weeks, months, or years after the initial infection, causing disease relapse.
Microscopic motile forms of malarial parasites are carried rapidly via the bloodstream to the liver. While in the liver, they invade hepatic parenchymal cells and begin a period of asexual reproduction. This process is known as an intrahepatic or pre-erythrocytic stage. P. ovale typically spends nine days in the pre-erythrocytic stage leading to the formation of sporozoites. P. ovale spends about 50 hours in an erythrocytic cycle. By the end of the 50 hours, the parasite has consumed nearly all of the hemoglobin and grown to occupy most of the red blood cell. At this stage, it is called a schizont. A single P. ovale sporozoite may produce about 15,000 daughter merozoites per infected hepatocyte.
Some P. ovale schizonts rupture and release merozoites into the circulation. Merozoites then invade red blood cells. While in the red blood cells, merozoites mature from ring forms to trophozoites and then to multinucleated schizonts. This state of maturation is called the erythrocytic stage. Schizonts that remain dormant are called hypnozoites. Hypnozoites are a dormant stage in the liver that can be seen in P. ovale as well as P. vivax infection. This dormant liver stage does not cause any clinical manifestations. Reactivation and release of hypnozoites into the circulation can lead to the late onset of the disease or relapse that can occur up to several months after the initial malaria infection.
Immediately after releasing of P. ovale from the liver, some merozoites develop into morphologically distinct male or female gametocytes that can transmit malaria infection. The Anopheles mosquito ingests these cells during a blood meal. The male and female gametocytes mature and form a zygote in the midgut of the mosquito. The zygote matures by asexual division and eventually releases sporozoites. The sporozoites then relocate to the mosquito's salivary glands. The mosquito completes its cycle of transmission by inoculating another human at the next feeding.
P. ovale typically infects young red blood cells, called reticulocytes. Giemsa stain reveals Schuffner dots under light microscopy. Infected erythrocytes are usually larger than normal. They can also be round, oval, or fimbriated. Trophozoites may be compact or irregularly shaped with sturdy cytoplasm and large chromatin dots. P. ovale gametophytes are usually round to oval while P. ovale schizonts have 4 to 16 merozoites with dark brown pigment.
A detailed history is essential to the timely and successful diagnosis of P. ovale malaria. Prompt and accurate diagnosis of this disease is critical for appropriate treatment to reduce associated morbidity and mortality. Initial symptoms are nonspecific. Patients usually present with a headache, fever, malaise, muscle aches, fatigue, diaphoresis (sweating), cough, anorexia, abdominal pain, diarrhea, and arthralgia.  Nausea, vomiting, and orthostatic hypotension are common.
Malaria should be suspected in the context of fever (temperature greater than or equal to 37.5 C) and relevant epidemiologic exposure including residence in or travel to an area where malaria is endemic.  Although a patient's headache may be severe, there is no neck stiffness or photophobia like in meningitis. Nausea, vomiting and orthostatic hypotension are common. When a patient presents with fever, chills, and rigors that occur at a regular interval, it suggests P. ovale malaria.
Clinical manifestations of severe malaria may occur with any malaria species, in the presence or absence of coinfection with P. falciparum.  These manifestations include hemodynamic instability, pulmonary edema, hemolysis, severe anemia, coagulopathy, hypoglycemia, metabolic acidosis, renal failure, hepatic dysfunction, altered mental status, focal neurological deficits, and seizures. Physical findings may include pallor, petechiae, jaundice, hepatomegaly, and splenomegaly. Diagnostic evaluations of severe malaria include parasitemia greater than or equal to 4% to 10%, anemia, thrombocytopenia, coagulopathy, elevated transaminases, elevated BUN/creatinine, acidosis, and hypoglycemia.  Although reports of severe P. ovale malaria are rare, splenic rupture, thrombocytopenia, and disseminated intravascular coagulation have been associated with P. ovale infection. 
For a patient with suspected P. ovale infection, the diagnostic method of choice is blood smear microscopy. Suspected malaria should be confirmed with a parasitologic diagnosis whenever possible. Microscopy (visualization of parasites in stained blood smears) and rapid diagnostic tests (RDTs) which detect antigen or antibody are clinical tools for parasite-based diagnosis. Detection of parasites on Giemsa-stained blood smears by light microscopy is the ideal method for laboratory confirmation of malaria. 
At least two thick and thin blood smears should be prepared as soon as possible after blood collection. Delay in preparation of smears can result in changes in parasite morphology and staining characteristics. Giemsa stain reveals Schuffner dots. Microscopy allows identification of the Plasmodium species as well as quantification of parasitemia. P. ovale infect only young erythrocytes, so parasite density for these species is typically lower. A parasitemia of greater than or equal to 5% is very unlikely with P. ovale or any other Plasmodium species except P. falciparum. The sensitivity of microscopy can be excellent, with the detection of malaria parasites at densities as low as 4 to 20 parasites per microliter of blood. 
RDTs should be used if microscopy is not available. RDTs for the detection of malaria parasite antigens are used in resource-limited endemic settings due to their accuracy and ease of use. They require no electricity or laboratory infrastructure and yield results within 15 to 20 minutes. RDTs provide a qualitative result but cannot provide quantitative information regarding parasite density. RDTs that detect antibodies produced by an infected host are also available, but these are less useful for diagnosing acute infection. There are no RDTs for definitive diagnosis of P. ovale.
Polymerase chain reaction is primarily a research tool. It typically detects as low as one parasite per microliter. Polymerase chain reaction diagnosis with a negative RDT may be useful where competent malaria microscopy is not available. 
Treatment of non-falciparum malaria consists of treating the erythrocytic forms. Also, treatment of infections caused by P. ovale requires eradication of liver hypnozoites to prevent relapse of the infection. Patients with uncomplicated infection due to P. ovale, and in the absence of other comorbidities, can usually be managed on an outpatient basis. Parasitemia should be monitored during treatment to confirm adequate response to therapy. Daily blood smears are appropriate to document declining parasite density until no parasitemia is detected or until 7 days of treatment have been completed. Patients on malaria prophylaxis who develop malaria infection should receive a different medication for treatment.
Chloroquine and or an artemisinin combination therapy (ACT) are used to treat P. ovale infection and other non-falciparum malaria infections. In areas with no endemic P. falciparum malaria, and chloroquine resistance remains low, chloroquine may be used with monitoring. ACT should be implemented when the chloroquine treatment failure rate at day 28 is greater than 10%.
Gametocytes of non-falciparum malaria species including P. ovale are susceptible to chloroquine. Chloroquine is highly effective against erythrocytic forms of P. ovale malaria infection.  Patients with mixed infections that include P. falciparum should receive definitive treatment for P. falciparum.
Primaquine is required to eradicate the hypnozoite liver stages of P. ovale.  Primaquine should be started after the fever has subsided and normal glucose-6-phosphate dehydrogenase status has been confirmed.
The P. ovale life cycle includes hypnozoites, which are dormant stages in the liver that can lead to relapse. The presence of hypnozoites in the liver does not cause systemic infection. Symptoms of relapse occur when reactivated hypnozoites are released into the systemic circulation. P. ovale malaria is not chloroquine resistant. Relapse due to P. ovale is relatively rare and may be prevented by administration of presumptive anti-relapse therapy like primaquine.
|||Mace KE,Arguin PM,Tan KR, Malaria Surveillance - United States, 2015. Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002). 2018 May 4 [PubMed PMID: 29723168]|
|||Tomar LR,Giri S,Bauddh NK,Jhamb R, Complicated malaria: a rare presentation of Plasmodium ovale. Tropical doctor. 2015 Apr [PubMed PMID: 25672340]|
|||Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally., Sutherland CJ,Tanomsing N,Nolder D,Oguike M,Jennison C,Pukrittayakamee S,Dolecek C,Hien TT,do Rosário VE,Arez AP,Pinto J,Michon P,Escalante AA,Nosten F,Burke M,Lee R,Blaze M,Otto TD,Barnwell JW,Pain A,Williams J,White NJ,Day NP,Snounou G,Lockhart PJ,Chiodini PL,Imwong M,Polley SD,, The Journal of infectious diseases, 2010 May 15 [PubMed PMID: 20380562]|
|||Kawamoto F,Liu Q,Ferreira MU,Tantular IS, How prevalent are Plasmodium ovale and P. malariae in East Asia? Parasitology today (Personal ed.). 1999 Oct [PubMed PMID: 10481157]|
|||Baird JK,Purnomo,Masbar S, Plasmodium ovale in Indonesia. The Southeast Asian journal of tropical medicine and public health. 1990 Dec [PubMed PMID: 2151542]|
|||Svenson JE,MacLean JD,Gyorkos TW,Keystone J, Imported malaria. Clinical presentation and examination of symptomatic travelers. Archives of internal medicine. 1995 Apr 24 [PubMed PMID: 7717795]|
|||Wilson ME,Weld LH,Boggild A,Keystone JS,Kain KC,von Sonnenburg F,Schwartz E, Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Jun 15 [PubMed PMID: 17516399]|
|||Hwang J,Cullen KA,Kachur SP,Arguin PM,Baird JK, Severe morbidity and mortality risk from malaria in the United States, 1985-2011. Open forum infectious diseases. 2014 Mar [PubMed PMID: 25734104]|
|||Devarbhavi H,Alvares JF,Kumar KS, Severe falciparum malaria simulating fulminant hepatic failure. Mayo Clinic proceedings. 2005 Mar [PubMed PMID: 15757017]|
|||Facer CA,Rouse D, Spontaneous splenic rupture due to Plasmodium ovale malaria. Lancet (London, England). 1991 Oct 5 [PubMed PMID: 1681259]|
|||Abanyie FA,Arguin PM,Gutman J, State of malaria diagnostic testing at clinical laboratories in the United States, 2010: a nationwide survey. Malaria journal. 2011 Nov 10 [PubMed PMID: 22074250]|
|||Dowling MA,Shute GT, A comparative study of thick and thin blood films in the diagnosis of scanty malaria parasitaemia. Bulletin of the World Health Organization. 1966 [PubMed PMID: 5296131]|
|||Proux S,Suwanarusk R,Barends M,Zwang J,Price RN,Leimanis M,Kiricharoen L,Laochan N,Russell B,Nosten F,Snounou G, Considerations on the use of nucleic acid-based amplification for malaria parasite detection. Malaria journal. 2011 Oct 28 [PubMed PMID: 22034851]|
|||Siswantoro H,Russell B,Ratcliff A,Prasetyorini B,Chalfein F,Marfurt J,Kenangalem E,Wuwung M,Piera KA,Ebsworth EP,Anstey NM,Tjitra E,Price RN, In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. Antimicrobial agents and chemotherapy. 2011 Jan [PubMed PMID: 20937779]|
|||John GK,Douglas NM,von Seidlein L,Nosten F,Baird JK,White NJ,Price RN, Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malaria journal. 2012 Aug 17 [PubMed PMID: 22900786]|